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Abstract
Treatment for chronic hepatitis C virus (HCV) infection has evolved consider-
ably in the last years. The standard of care (SOC) for HCVinfection consists in
the combination of pegylated interferon (PEG-IFN) plus ribavirin. However,
it only induces a sustained virological response (SVR) in half of genotype
1-infected patients. Several viral and host factors have been associated with
non-response: steatosis, obesity, insulin resistance, age, male sex, ethnicity and
genotypes. Many studies have demonstrated that in non-responders, some
interferon-stimulated genes were upregulated before treatment. Those ﬁnd-
ings associated to clinical, biochemical and histological data may help detect
responders before starting any treatment. This is a very important issue
because the standard treatment is physically and economically demanding.
The future of HCV treatment would probably consist in the addition of
speciﬁcally targeted antiviral therapy for HCV such as protease and/or
polymerase inhibitors to the SOC. In genotype 1 patients, very promising
results have been reported when the protease inhibitor telaprevir or boceprevir
is added to the SOC. It increases the SVR rates from approximately 50%
(PEG-IFN plus ribavirin) to 70% (for patients treated with a combination of
PEG-IFN plus ribavirin plus telaprevir). Different elements areassociated with
non-response: (i) viral factors, (ii) host factors and (iii) molecular mechan-
isms induced by HCV proteins to inhibit the IFN signalling pathway. The goal
of this review is to present the mechanisms of non-response, to overcome it and
to identify factors that can help to predict the response to anti-HCV therapy.
Hepatitis C virus (HCV) is among the leading causes
of chronic liver disease worldwide and affects
approximately 170 million people (1–3). HCV has been
identiﬁed in 1989 as an enveloped virus with a 9.6kb
single-stranded RNA genome, member of the Flaviridae
family, genus Hepacivirus (4–8). Six genotypes of HCV
(from 1 to 6) and various subtypes have been identiﬁed
(5). The severity of the disease associated with HCV
infection varies from asymptomatic chronic infection to
cirrhosis and hepatocellular carcinoma (1, 9).
Treatment of HCV using combination of pegylated
interferon (PEG-IFN) plus ribavirin fails in about 50% of
the patients and is physically and economically demand-
ing. Thus, it is highly important to understand the mechan-
isms of non-response to overcome it and to identify
factors that can help to predict the chance of each patient
to respond to the treatment. Different elements are
associated with non-response: (i) viral factors, (ii) host
factors and (iii) molecular mechanisms induced by HCV
proteins to inhibit the IFN signalling pathway. The goal
of this review is to present the different factors associated
with non-response to the current treatment against HCV
(Fig. 1).
Activation of interferon pathway
Interferon type 1 are the major antiviral cytokines. HCV
infection may induce host signalling pathways leading to
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induce IFN signalling pathways; the double-stranded
RNA is recognized by cellular pattern recognition recep-
tor such as TLR3 and RIG-I.
Although HCV is a single-stranded RNA virus, its
replication may produce some dsRNA because of its
RNA-dependent RNA polymerase NS5B. This dsRNA
may activate the IFN signalling pathway (13).
The activation of TLR3 after the binding of dsRNA
activates a cascade of events. IRF3 is phosphorylated and
transcription factors such as NFkB and AP-1 are acti-
vated. Phosphorylated IRF3 forms a dimer and translo-
cates into the nucleus where it binds to DNA to regulate
the expression of IFNb.
Receptors such as RIG-I and Mda5 recruit the IFNb
promoter stimulator 1 (IPS-1 or cardif) after the binding
of dsRNA (10). IPS-1 plays an important role in the
activation of IRF3, IRF7 and NFkB. IRF-7 forms a dimer
and translocates into the nucleus to induce IFN a/b.
IRF-3 dimers collaborate with NFkB also to induce
IFN a/b.
Interferon a/b binds to a receptor at the cell surface,
inducing the activation of the Jak/STAT signalling path-
way. In collaboration with IRF-9 and ISGF3, Jak/STAT
signalling induces the activation of IFN-stimulated re-
sponse elements activating the transcription of IFN a/b-
stimulated genes (12).
This ﬁnally results in the production of proteins such
as RNAse L and protein kinase R that will target the
degradation of viral RNAs and block their translation
(14) (Fig. 2).
Deﬁnition of non-response
The standard of care (SOC) consists in the combination
of PEG-IFN with ribavirin (15–19). The duration of the
treatment can vary depending on the genotype. Forty-
eight weeks are recommended for patients infected with
genotypes 1 and 4, while patients with genotypes 2 and 3
are treated only for 24 weeks.
The goal of such a treatment is to obtain a sustained
virological response (SVR) deﬁned as undetectable HCV
RNA in the serum after 24 weeks of post-treatment
follow-up (15). This SVR results in the eradication of
HCV infection and improvement of the histological
outcome (20).
During the whole period of the treatment, HCV RNA
load is monitored. Flat non-responders show no variation
of the HCV RNA. Patients achieving an early virological
response (more than 2log10 reduction in HCV RNA
load compared with the baseline or HCV RNA negative,
at week 12) or a rapid virological response (RVR) (HCV
RNA negative at treatment week 4) have a better chance
of maintaining an SVR (15, 21–25) (Fig. 3).
Although a signiﬁcant percentage of patients with
chronic hepatitis genotypes 1 and 4 require 48 weeks of
therapy, those with RVR might be treated for 24 weeks.
Viral factors responsible for non-response to
interferon treatment
Genotype
Hepatitis C virus genotype is the strongest baseline
predictor of IFN response. So far, 6 genotypes (1–6) have
been described based on a sequence divergence. In the
same genotype group, variants share at least 70% of
sequence homology. Genotype 1 (subtypes 1a and 1b) is
the most common in Europe, followed by genotypes 2
and 3. Genotypes 4–6 are less common, but are starting
to be observed more frequently because of increasing
cultural diversity.
The actual SOC therapy, in a patient with hepatitis C,
yields a sustained response in approximately 55% of the
Fig. 1. Factors associated to non-response to pegylated interferon plus ribavirin treatment.
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rates reaches 80%, while with genotype 1, patients SVR
rates is only 50%. Finally, response rates for genotype 4
are higher than those for genotype 1, but lower than
those for genotype 3 (approximately 65%).
Genetic diversity
During its replication, HCV has the particularity to
generate some quasispecies. Two quasispecies are char-
acterized by at least 90% of nucleotide sequence homol-
ogy (20, 26, 27). Thus, sensitivity to HCV therapy can be
variable, because in this 10% of genetic divergence, it is
possible to generate some viral variants with a different
sensibility to the treatment.
In a recent study (28), the authors analysed the amino
acid sequence of about 100 patients before treatment
with IFN plus ribavirin. They show that the HCV
sequence of non-responders presents three-fold more
hydrophobic pairs of amino acids than the sequence of
responders. These hydrophobic amino acids were pre-
dicted to contribute to IFN treatment failure by stabiliz-
ing the HCV proteins complex. The authors report that,
using these algorithms, they were able to predict response
to the treatment in 95% of the patients. Although these
results are promising, they need to be conﬁrmed in
further studies.
Mutation in several subgenomic regions of HCV have
been related to sensitivity to IFN treatment. Two amino
acid regions of NS5A have been described and are
Fig. 2.HepatitisC virus (HCV)and immuneresponse. Activationof toll like receptor3 (TLR3)leadsto the recruitment ofIkB kinase(IKK)-related
kinases, TANK-binding kinase 1 (TBK1) and IKKi. These kinases, together with adaptators TANK and NAP1, catalyse the phosphorylation of
interferon (IFN) stimulatory factor-3 (IRF-3). Phosphorylated IRF-3 forms a dimer, translocates into the nucleus, binds to DNA in collaboration
with transcription factor AP-1 and NF-kB and regulates the expression of IFNb. The HCV NS3-4A serine protease may block the
phosphorylation and effector action of IRF-3. After recognition of viral RNA, RIG-I and Mda5 recruit IFNb promoter stimulator-1 (IPS-1) via
caspase recruitment domain (CARD-CARD) interaction. IPS-1 is localized in the mitochondria and acts as an adaptator that plays a critical role
in the activation of IRF-3 and IRF-7. IPS-1 is targeted and inactivated by the serine protease NS3/4A from HCV. IRF-7 forms a dimmer and
translocates into the nucleus to induce IFN a/b. Endogenous IFN a/b bind to a common receptor (IFNAR-1/2) expressed at the cell surface of
target cells. Receptor engagement leads to recruitment of Tyk2 and Jak1. Together with IRF-9 the two kinases induce activation of STAT1 and
STAT2 which, together with ISGF3G/IRF9, bind to cis-acting IFN stimulated elements (ISREs), thereby activating the transcription of IFN a/b-
inducible genes such as PKR, IL-8, OAS . The HCV core protein has been shown to induce the expression of SOCS3 (suppressor of cytokine
signalling 3), which can suppress Jak/STAT.
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(i) IFN sensitivity-determining region (29, 30) (ii) IFN/
ribavirin resistance-determining region (IRRDR) (31). In
both cases, the authors showed that the high number of
mutations within these amino acid sequences (more than
six in the case of IRRDR) is signiﬁcantly associated with
higher rates of SVR. However, these results need con-
ﬁrmation; other studies in other population of
patients have not conﬁrmed these data (32). Mutations
within E2-PePHD, NS5A-PKRBD and NS5A-V3 have
been reported later (33, 34). These mutations have been
implicated in inﬂuencing the response to IFN therapy.
Baseline viral load
Interestingly, several studies have demonstrated that the
chance to respond to IFN treatment is related to the
baseline viral load. Patients with a high viral load
4800000UI/ml (2 millions of copies/ml) are less sensi-
tive to the treatment than patients with a low viral load
o800000UI/ml (21–24, 35–37). Thus, patients with
genotype 1, low baseline viral load and RVR may be
treated for 24 weeks, while patients with genotype 3, high
baseline viral load and without RVR may require 48
weeks of treatment.
Viral kinetics
Although PEG-IFN plus ribavirin induced an SVR in
80% of patients infected by genotype 2 or 3, only 50% of
the patients with genotype 1 present an SVR.
When response rates are low (genotype 1 and 4),
kinetics of the virus during the ﬁrst weeks of the
treatment are valuable indicators. The presence of an
RVR, EVR or no signiﬁcant decrease of viral load helps to
predict the chance of achieving an SVR.
Patients who present an RVR have a greater chance of
achieving an SVR (higher than 85%) (25). Patients who
do not present any decrease of the viral load will not be
able to respond to the treatment (35, 38–40).
Host factor responsible of non-response to
interferon treatment
Responsiveness to hepatitis C virus therapy depends not
only onviral factors but also on host factors. Age, gender,
cirrhosis, steatosis, insulin resistance, diabetes, African
American ethnicity and weight (BMI) are all events
associated to poor response to pegylated-IFN plus riba-
virin treatment. Insulin resistance, obesity and steatosis
are also associated with a higher risk of ﬁbrosis progres-
sion (41, 42). The adherence of each patient is highly
variable. Chances of achieving an SVR signiﬁcantly
decrease when patients receive o80% of the total dose
of peg-IFN and/or o80% of total ribavirin and/or
during o80% of the total period of treatment (43).
Comorbidities such as HIV and/or HBV co-infection,
excess alcohol intake and drug use are generally associated
with lower SVR rates (44). It seems that cannabis receptor
stimulation is associated with lower response to IFN treat-
ment (45). However an interesting study showed that
occasional users of cannabis should not stop their consump-
tion because at a low –dose, cannabis does not signiﬁcantly
inhibit IFN treatment but should reduce their observance.
Moreover, it has been recently reported that patients
with a history of depression who were not receiving
antidepressants and active intravenous drug users are
more likely to fail treatment for genotype 2/3 HCV and
will need additional support (46).
Insulin resistance has been shown to reduce the
chances of achieving an SVR (47, 48). Both impaired
fasting glucose and type-2 diabete mellitus are associated
with lower rates of SVR in patients treated with peg-IFN
and ribavirin. The use of insulin-sensitizing agents such
as pioglitazone to HCV treatment increases both SVR
and RVR rates (49). HCV expression induces insulin
resistance (47). The core protein, through activation of the
Januse Kinase pathway, inhibits the activity of insulin
receptor 1 (IRS1) (50, 51). Moreover, expression of the core
proteininducestheactivationoftheSOCS-3protein,which
i n c r e a s e dt h ed e g r a d a t i o no fb o t hI R S 1a n d2( 5 2 ) .
In 2006, the protein USP18 has been reported to
modify pharmacokinetic of IFN. USP18 is thought to
inhibit the effect of IFN therapy by reducing its
Fig. 3. Deﬁnition of response to pegylated interferon (PEG-IFN) plus
ribavirin treatment. The kinetic of HCV RNA level during PEG-IFN
plus ribavirin therapy helps to predict the response. Rapid virological
response (RVR) is deﬁned as a HCV RNA negative at treatment week
4. Early virological response (EVR) consists in a reduction of HCV
RNA 42 log compare to HCV RNA baseline, at week 12. A
complete EVR is deﬁned as a negative HCV RNA at the end of the 24
or 48 weeks of the treatment. Sustained virological response (SVR) is
characterized by an absence of HCV RNA, up to 24 weeks after
cessation of treatment. Reappearance of HCV RNA in the serum
during the treatment is deﬁned as a breakthrough. The term of
relapse is used when HCV RNA level is again detectable when the
therapy is discontinued. Finally, patients who do not respond to the
treatment are described as (i) non-responders when they fail to clear
HCV RNA after 24 weeks of therapy, or (ii) Null responders when
they fail to clear the HCV RNA level up to 2 log at week 24 of the
therapy, or (iii) Partial responders when they achieved a EVR and
show HCV RNA level still detectable at week 24 of the therapy.
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sion has been associated with non-response to IFN treat-
ment (53). Therapy targeting USP18 could be used in the
future to limit its inhibitory effect and thus to increase
SVR rates.
Identiﬁcation of new molecular markers related to
non-response
Because of the important side effects and high cost of
PEG-IFN plus ribavirin therapy, it is highly important to
identify some molecular markers that can discriminate
patients who will not respond to the treatment.
Single nucleotide polymorphism, genome wide
association studies
Large-scale and genome-wide association studies have
attempted to identify a molecular pattern associated with
responsiveness to IFN treatment. An SNP is a modiﬁca-
tion of one nucleotide of the genome sequence. It can
occur in a coding region or in a non-coding region as well.
Thus, in some particular cases, it exerts a direct effect on
protein activity or expression.
Lin et al. (54) used an artiﬁcial neural network to
address this kind of interaction in the antiviral treatment
response for 523 patients with chronic hepatitis C. These
patients had received IFN plus ribavirin treatment; 350
were sustained responders, while 173 were non-responders.
They focused on 6 candidates genes involved in the IFN
pathway (ADAR, CASP5, ISCBP1, IFI44, PIK3CG and
TAP2). A total of 20 single nucleotide polymorphisms
(SNPs) have been selected. The results of this study strongly
support the notion that viral genotype and IFI44, members
of interferon-stimulated genes (ISGs), play a role in the
pharmacodynamic of IFN treatment (54).
Another study, by Huang et al. (55) in 2007, identiﬁed
eight SNPs, spanning the entire IFN-g gene in two
different cohorts. The authors assessed the association
between those polymorphisms and treatment response
or clearance of the virus. Interestingly, an SNP variant
located in the proximal IFN-g promoter region next to
the binding region of the heat shock transcription factor
(HSF) C764G was signiﬁcantly associated with SVR.
Functional analyses show that the G allele confers a
higher promoter activity and a stronger binding afﬁnity
for HSF1. The study suggests that the IFN-g promoter
SNP C764G is functionally important in determining
viral clearance and treatment response to IFN (55).
Gene expression in liver biopsies and/or serum from
responders and non-responders has been compared.
Hwang et al. (56) isolated seven genes associated to
responsiveness (ADAR, CASP5, FGF1, ICSBP1, IFI44,
TAP2 and TGFBRAP1). These genes have been used to
construct a signature model by multiple logistic regres-
sion. The sensitivity was only 68% and the speciﬁcity was
60%. The model did not investigate gene–gene and
gene–environment interactions (56) (Table 1).
In 2009–2010, four independent genome-wide
association studies reported SNPs, in the IL28B (IFN-
l3) region, associated with response to treatment
(57–60). All patients tested received the SOC (pegylated
interferon plus ribavirin). Interestingly, different
ethnicities (European, African American, Australian and
Japanese) have been included and compared in these
three studies.
Ge et al. (57) analysed 1137 patients with HCV
genotype 1 infection, and they identiﬁed several SNPs
near the IL-28B gene on chromosome 19 that were
signiﬁcantly more common in responders than in non-
responders. A study by Thomas et al. (61) reports that
the same IL-28B variant, described by Ge and colleagues,
is also associated with a spontaneous clearance of HCV.
A strong association of rs12979860 with both EVR
and SVR in IFN-naive patients treated with Peg-IFNa-
2a/ribavirin was also reported (62). These results extend
previous ﬁndings to show EVR and SVR associations in
patients treated with Peg-IFNa-2a monotherapy and
with conventional IFN/ribavirin. Additionally, we rank
all previously described SNPs and ﬁnd that rs12979860
drives the association with response. Finally, we highlight
the association of rs12979860 with early HCV decline in
response to IFN treatment.
IFN-ls, including IFN-l1, 2 and 3 (also known as
IL-29, IL-28A and IL-28B), are a newly described group
of antiviral cytokines distantly related to type I IFNs and
IL-10 family members (63,64). The IFN-l receptor com-
plex consists of a unique ligand-binding chain, IFN-lR1
(also designated IL-28Rl), and an accessorychain, IL-10R2,
which is shared with receptors for IL-10-related cyto-
kines. IFN-ls binding to its receptor activates pathways of
JAK-STATs and MAPKs and induces antiviral, antiproli-
ferative, antitumour and immune responses. IFN-l pro-
teins seem to have a lower antiviral activity than IFN-a
in vitro (63). IFN-l1 has been shown to exhibit dose- and
time-dependent HCV inhibition, to increase ISGs expres-
sion, and to enhance the antiviral efﬁcacy of IFN-a (64).
Although all of the identiﬁed variants in the three
studies lie in or near the IL-28B gene, none of them has
an obvious effect on the function of this gene.
Furthermore, genetic variants leading to inosine tri-
phosphatase deﬁciency, a condition not thought to be
clinically important, protect against haemolytic anaemia
in hepatitis-C-infected patients receiving RBV. Two ITPA
polymorphisms known to be responsible for inosine tri-
phosphatase deﬁciency cosegregate with the rs6051702 C
allele that strongly associates with protection against hae-
m o g l o b i nr e d u c t i o ni nE u r o p e a nA m e r i c a n s( 6 5 ) .
Transcript gene expression
Liver gene expression has been used to determine re-
sponse to the treatment. Differential expression of genes
directly and indirectly implicated in the mechanism of
response to PEG-IFN and ribavirin can explain the
variation of the treatment efﬁciency. Gene expression
Liver International (2010)
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polymerase chain reaction or microarray studies. Gene
expression in responders and non-responders has been
compared, in a study, it reported to ISGs upregulated in
non-responder patients (66). This observation suggests a
possible rationale for treatment resistance.
The expression proﬁle of a selection of genes related to
liver dysregulated during HCV infection has been ana-
lyzed according to the response to the treatment. A two-
gene signature has been successfully identiﬁed, IFI27 and
CXLC9 (67). This signature predicts the response to the
treatment in 79% of the patients, with a predictive
accurancy of 100% in non-responders and 70% in
sustained virological responders (67). The results also
suggest that ISGs are upregulated in non-responders
before treatment.
Gene expression analysis in peripheral blood mono-
nuclear cells are actually lacking for HCV. Analyzing
genes expression in PMBC rather than in liver biopsie
represents an insight for patients because it does not need
any invasive exploration. Many of the genes found to be
upregulated between non-responders and responders encode
molecules secreted in the serum (cytokines) (68, 69). Thus,
they could be used in the development of serums markers as
predictors of response to HCV treatment.
In a recent study, authors demonstrated that an early
expression of interferon-dependent genes can help to
predict response rates to PEG-IFN plus ribavirin
Table 1. Host genetic diversity and response to interferon
Authors Year Technology
Number of
patients Identiﬁed targets
Genome-wide association studies
Hwang et al. (56) 2006 217 (195 R
and 122 NR)
26 SNPs in seven genes:
ADAR, CASP5, FGF1,
ISCBP1, IFI44, TAP2,
TGFBRAP1
Lin et al. (54) 2006 DNA extraction from whole blood,
polymorphism genotyping and artiﬁcial
neural network
523 20 SNPs in six genes
ADAR, CASP5, ISCBP1,
IFI44, PK3CG and TAP-2
Huang et al. (55) 2007 DNA extraction from whole blood,
polymorphism genotyping
284 Eight SNPs in IFN-g
IFN-g 764G/C is associated
with IFN response
Ge et al. (57) 2009 Blood 1137 Upstream IL-28B
Tanaka et al. (59) 2009 Blood 154172 Upstream IL-28B
Suppiah et al. (58) 2009 Blood 555 Upstream IL-28B
Rauch et al. (60) 2010 Blood 1362 Upstream IL-28B
Asselah et al. (62) 2010 Blood 832 Upstream IL-28B
Gene expression studies (transcriptome)
Chen et al. (66) 2005 mRNA extraction and RT-PCR on liver
biopsies
51 (15 NR, 16 R,
20 control)
18 interferon-stimulated
genes (ISGs) including
ISG15 and USP18
Asselah et al. (67) 2008 mRNA extraction and RT-PCR on liver
biospies
69 IFI-6-16, IFI27, ISG15,
MX1, HERC15, TGFB2,
OAS2, VEGFD, IL8, IFIT1
Younossi et al. (70) 2009 mRNA extraction and RT-PCR on PBMC 68 STAT6, suppressor of
cytokine signalling 1
Thomas et al. (61) 2009 Blood, genotype cohorts for rs12979860
3kb upstream IL-28B
3881620 Upstream IL-28B
Sarasin-Filipowicz et al. (80) 2009 Liver biopsies 42 Decreased miR-122 in
non-responders
Studies performed on serum
Butera et al. (68) 2005 Immuno-quatiﬁcation in plasma samples 58 CXCL9 and CXCL10
decrease and
CXCL11=after effective
antiviral therapy
Paradis et al. (71) 2006 Surface-enhanced laser desorption
ionization time-of-ﬂight massspectrometry
on serum samples
96 37 protein peaks in
responders and two in
non-responders
Younossi et al. (70) 2009 mRNA extraction and RT-PCR on PBMC 68 STAT6, suppressor of
cytokine signalling 1
IFN, interferon; IL, interleukin; RT-PCR, real-time polymerase chain reaction.
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and results showed that SVR could be predicted by the
gene expression of the signal transducer and activator of
transcription-6 (STAT-6) and suppressor of cytokine
signalling-1 in pretreatment samples. Interestingly, even
after 24h of treatment, interferon-dependent genes ex-
pression can help to predict the probability of achieving
an SVR (70) (Table 1).
Serum studies
One study investigated the binding to the CXC chemokine
receptor 3 (CXCR3). Interestingly, they demonstrated that
the binding of CXCL 10 and CXCL9 decrease during
successful anti-HCV treatment, while CXCL11 level is not
signiﬁcantly modiﬁed (68). Those results are very promis-
ing and these data should be validated in large cohorts
before being used as predictors of SVR during treatment.
In a proteomic study of our group, the authors have
compared serum proteins expression of 96 patients with
chronic hepatitis C (71). Using logistic regression to
predict response to the treatment (PEG-IFN plus ribavir-
in in 89% of all patients), two protein peaks have been
identiﬁed. Moreover, this algorithm had been used to
predict the response to PEG-IFN plus ribavirin in an
independent group of patients. The response was pre-
dicted correctly in 81% of the patients (71) (Table 1).
Interaction of hepatitis C virus with interferon
pathway
Hepatitis C virus infection induced the IFNb pathway.
During its replication, some dsRNA are generated, and
they represent signals that induce the IFN pathway
through binding to receptor such as TLR3. Thus, several
transcription factors are recruited to activate the tran-
scription of IFNb.
Some proteins of HCV have been well described for
their interaction with the IFN pathway. NS3-4A shows
two major anti IFN activities: (i) NS3-4A mediates the
cleavage of the C-terminal region of IPS-1/cardif, causing
the disruption of NF-kB and IRF-3 activation, probably
due to mislocalization of cleaved IPS1/cardif from the
mitochondria and (ii) NS3-4A also mediates TRIF pro-
teolysis (11). Thus, HCV proteins may block both TLR
and RIG-I-Mad5-dependent signalling pathways to an-
tagonize type I IFN induction. The NS3-4A is a dual
therapeutic target whose inhibition may block viral
replication and restore IRF-3-dependent control of
HCV infection.
Some HCV-related effect may also contribute to
attenuation of the IFN pathway. It has been reported that
the HCV core protein induce the activation of the
suppressor of cytokine signalling 3 (SOCS3) (72). SOCS
proteins are known to inhibit cytokine via the JAK/STAT
pathway. HCV proteins expression is associated with the
accumulation of the proteins phosphatase 2A. Patients
with chronic hepatitis C present higher levels of PP2A
expression in liver tissue (73). It has been reported that
the methylase PRMT1 targets methylation of NS3 on
arginine 1493 (in the polyprotein), thus leading to the
inhibition of its helicase activity (74). PP2A inhibits
PRMT1 methylase activity. It is thought that accumula-
tion of PP2A in patients with chronic hepatitis C,
through inhibition of PRMT1, maintains NS3 helicase
activity to stimulate HCVreplication (74).
A recent study assessed the efﬁciency of antipolymer-
ase and antiprotease to overcome the inhibitory effect of
viral protein expression on the IFN signalling pathway.
Interestingly, while antipolymerase does not revert the
inhibitory effect of the polymerase, the two antiprotease
used counteract NS3/4A protease inhibition, but only in
a concentration far in excess (75).
MicroRNAs and hepatitis C virus infection
MicroRNAs (miRNAs) are a class of small non-coding
RNA molecule of 20–22 nucleotides that control gene
expression by targeting mRNAs for transcriptional re-
pression or cleavage. They are involved in the regulation
of crucial cellular mechanisms such as development, cell
differentiation, proliferation and apoptosis.
The importance of the miRNAs machinery in HCV
replication has been recently described invarious studies.
For example, silencing of the RNAse III Dicer by siRNA
inhibits HCV replication by about seven-fold (76). miRNA
122 represents 70% of the miRNA expressed in the liver
tissue. Moreover, depletion of miRNA 122 in Huh7 hepa-
toma cells is associated with inhibition of HCV replication
and infectious viral production (77). It is thought that
miR-122 binding stabilizes the association of HCV mRNA
with the ribosome stimulating the translation (78).
These ﬁndings suggest that HCV takes advantage of
the presence of miR-122 in hepatocytes, which may be a
target for novel approaches in the treatment of HCV
infection. Interestingly, IFNb was found to rapidly mod-
ulate the expression of numerous cellular miRNAs
in vitro, and eight of these IFN- b-induced miRNAs were
shown to have sequence-predicted targets within the
HCV genomic RNA (79). Moreover, IFN-b results in a
signiﬁcant reduction in miR-122 expression. These ﬁnd-
ings strongly support the notion that the human organ-
ism uses cellular miRNAs to overcome HCV infection
through the IFN system, and also adds a new component
to the antiviral arsenal of IFNs.
However, according to a recent report, it appears that
there is no correlation of miR122 expression in the liver
with viral load. Moreover the author showed that non-
responders present signiﬁcantly decreased loads of miR122
expression before any treatment (80).
In 2010, Lanford et al. (81) demonstrated that treat-
ment of chronically infected chimpanzees with a locked
nucleic acid-modiﬁed oligonucleotide (SPC3649) com-
plementary to miR-122 leads to long-lasting suppression
of HCV viraemia, with no evidence of viral resistance or
side effects in the treated animals. Furthermore,
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demonstrated derepression of target mRNAs with miR-
122 seed sites, downregulation of interferon-regulated
genes and improvement of HCV-induced liver patho-
logy. The prolonged virological response to SPC3649
treatment without HCV rebound holds promise of a new
antiviral therapy with a high barrier to resistance (81).
In 2009, the miRNA 199a has been reported to be a
strong regulator of HCV infection. Binding of miRNA
199a targets HCV genome degradation and limits viral
replication (82). The authors used a miRNAtarget search
algorithm and identiﬁed miRNA 199a that targets the
HCV genome. They demonstrated that speciﬁc miRNA
effectively acts as an RNA silencing-based antiviral
response during HCV replication with miRNA-speciﬁc
machinery. The present study suggests that miRNA
mediated HCV inhibition and it may be possible to apply
it for the development of novel anti-HCV therapies.
How to overcome non-response?
There are two major ways to achieve higher rates of SVR:
(i) increase the efﬁciency of the current treatment by
modifying the factors of non-response such as obesity,
alcohol and drug consumption and later by adding
STAT-C to the SOC and (ii) detect non-responders before
beginning any treatment.
Several studies have demonstrated that some ISGs are
upregulated in non-responders before the treatment (67).
Combining those results to genotype and ﬁbrosis score
will give strong indications about the chance of each
patient to respond to the treatment.
Because of adverse effects, it is important to be able to
limit as much as possible treatment that will fail.
On the other hand, new drug therapies such as anti-
viral protease and antipolymerase are under develop-
ment. The protease inhibitor NS3/4A telaprevir is being
developed by the companies Vertex (Cambridge, MA,
USA) and Tibotec (Mechelen, Belgium). The results of
the phase IItrial have been recently published (83, 84). In
these studies, the anti protease has been combined to
PEG-IFN 1/ ribavirin. Adding telaprevir to the SOC
presents two signiﬁcant advantages: (i) it increases SVR
rates from approximately 50 to 70% in patients with
genotype 1 and (ii) the duration of the treatment can be
reduced from 48 to 24 weeks. Response rates were lowest
with the regimen that did not include ribavirin. However,
telaprevir regimen is related to higher discontinuations
because of adverse events (mainly cutaneous rash) (83, 84).
Boceprevir (Schering Plough, Kenilworth, NJ, USA) is
a small molecule, which is a speciﬁc inhibitor of the viral
protease NS3/4A. After 14 days of monotherapy at
400mg, three times/day, the viral load was signiﬁcantly
reduced by approximately 1.5log in non-responders to
PEG-IFN. Moreover, the association of PEG-IFN 2b with
boceprevir resulted in a marked reduction in viral load of
approximately 2.5log after 13 days of treatment in non-
responders to PEG-IFN 1/ ribavirin (85).
In genotype 1 patients, when boceprevir is combined
with SOC, it appears safe for use up to 48 weeks and sub-
stantially improves SVR rates with 28 weeks of therapy.
In this trial, 48 weeks of boceprevir treatment almost
doubles the SVR compared with the current SOC (86).
A 4-week lead-in with SOC before the addition of
boceprevir appeared to reduce the incidence of viral
breakthrough.
In HCV-genotype 1 infected patients in whom initial
peginterferon a and ribavirin treatment failed, retreat-
ment with telaprevir in combination with pegiinterferon
a-2a and ribavirin (approximately 50%) was more effective
than retreatment with peginterferon a-2a and ribavirin
alone (approximately 15%) (87). Polymerase inhibitors
interfere with viral replication by binding to the
NS5B RNA-dependent RNA polymerase. Two types of
polymerase inhibitors are actually under development: (i)
nucleoside analogue and (ii) non-nucleosides inhibitors.
Nucleoside analogues act as chain terminators; they
interfere with the initiation of RNA transcription and
elongation. In contrast to the nucleoside analogues that
target the active site of HCV polymerase, non-nucleoside
inhibitors have been designed to bind to several discrete
sites on HCV polymerase. The resistance proﬁles of
nucleoside analogues, non-nucleoside inhibitors and
protease inhibitors are all distinct from each other. Thus,
it is possible that agents from different classes will act in a
complementary manner to increase their efﬁciency and
prevent the development of resistance.
The future of chronic hepatitis C therapy seems to be
in the combination of these different drugs with different
sites of action (protease and polymerase inhibitors),
maybe even in interferon-free regimens. The potential
advantages of these combinations should be additive or
synergistic antiviral effects, and decrease the occurrence
of viral resistance. Unfortunately, so far, few data are
available. With the availability of the resistance proﬁle of
the future molecules, we should be able to avoid cross
resistance.
Conclusion
Interferon responsiveness remains a major clinical pro-
blem in the eradication of HCV, even with the use of new
drugs such as protease and polymerase inhibitors.
Some factors associated with low response rates can-
not be modiﬁed such as male sex, ethnicity, age and
genotype, although other factors such as steatosis, drug
and alcohol consumption, insulin resistance, and obesity
can be controlled and chances of a patient to achieve an
SVR could increase.
It has been shown that in non-responders, some ISGs
were highly expressed; thus, preactivation of the IFN system
in patients appears to limit the effect of IFN antiviral
therapy.
Moreover, HCV proteins encode some activities to
interfere and limit the IFN signalling pathway. The next
step of anti-HCV therapy would probably consist in two
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such as protease and polymerase inhibitors or drugs that
help restore the IFN signalling pathway, and second, the
detection of non-responders based on several factors
including ISG expression. It would be important to
identify genetic and molecular markers that might pre-
dict response. However, such markers need to be sensi-
tive and speciﬁc, feasible and easy to assess. Protease
inhibitors will be registered for genotype 1 patients since
they are speciﬁc for genotype 1 and not for genotype 2, 3
or 4. The direct antiviral effect of new molecules could
reverse IFN resistance. The hope for the next future is
that new therapeutic strategies would overcome non-
response.
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